The Biomarker Profile of Alzheimer’s Disease for Disease-Modifying Treatment Eligibility: Questions and Debates
Athanasia Athanasaki, Ioanna Tsantzali, Aikaterini Theodorou, Amalia Michalopoulou, Vasilios C. Constantinides, Fotini Boufidou, John S. Tzartos, Panagiota-Eleni Tsalouchidou, Christina Zompola, Sotirios G. Paraskevas, Anastasios Bonakis, Sotirios Giannopoulos
TL;DR
This paper reviews the ongoing debates about which biomarkers are needed to confirm Alzheimer's disease and determine eligibility for treatments.
Contribution
The paper provides a critical discussion on unresolved questions regarding biomarker profiles for Alzheimer's disease treatment eligibility.
Findings
There is debate over whether amyloid positivity alone is sufficient for treatment eligibility.
The role of tau biomarkers and hybrid ratios remains controversial.
Uncertainty exists about the reliability of plasma biomarkers alone for diagnosis.
Abstract
Alzheimer’s disease (AD) is the most common cause of cognitive decline; currently, anti-amyloid monoclonal antibodies are available for clinical use as disease-modifying treatments, while many other substances are being tested in clinical trials. Molecular biomarkers for AD have been studied for more than two decades, and various guidelines and diagnostic recommendations have been published. However, there are still questions and controversies about the biomarker profile needed to confirm AD and the eligibility for such established treatments and clinical trials. Is amyloid positivity sufficient for eligibility, or is a biomarker for tau biochemistry/pathology also needed? What is the role of hybrid ratios combining amyloid and tau? Should we rely on plasma biomarkers alone? This review aimed to describe and discuss such questions and controversies.
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsAlzheimer's disease research and treatments · Dementia and Cognitive Impairment Research · Cholinesterase and Neurodegenerative Diseases